Arizona Tribune - Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv

ANN ARBOR, MI / ACCESS Newswire / December 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, is thrilled to announce that its Assisi^® and Calmer Canine^® products are featured in the new romantic comedy Merv, available now on Prime Video.

Zomedica Brings Real Pet Wellness Technology to the Big Screen

In an exciting collaboration with Prime Video, Zomedica's Assisi and Calmer Canine technologies are featured in Merv, a feel-good romantic comedy starring Zooey Deschanel and Charlie Cox.

The film follows Anna (Deschanel) and Russ (Cox), when their beloved dog Merv loses his spark after their split. They are forced into the world's most awkward co-parenting arrangement.

Hoping to shake Merv out of his funk, Russ takes him to Florida for a much-needed getaway - Only for Anna to show up unexpectedly. As Merv slowly gets his groove back, Anna and Russ find out fixing their dog's broken heart may lead to a few sparks of their own.

"We're beyond excited to see our Assisi and Calmer Canine product lines featured in Merv and to collaborate with Prime Video on such a meaningful project," said Nicole Westfall, Senior Vice President of Marketing at Zomedica. "This collaboration shines a light on the emotional connection people share with their pets, and how innovations like ours help animals heal and thrive. Collaborating with Prime Video to authentically depict compassionate, real-world pet care is an incredible opportunity to expand awareness of Zomedica's mission while highlighting the amazing human-animal bond that takes place in families around the world."

"This collaboration enabled us to deepen engagement with pet parents who make up such an important part of our audience. With an adorable dog at the center of this film, teaming up with the pet wellness experts at Zomedica made perfect sense," said Gregory Coleman, Head of Integrated Marketing at Amazon MGM Studios.

As part of this collaboration, Prime Video and Zomedica will co-promote Merv through coordinated digital, social, and educational campaigns designed to engage pet parents, veterinarians, and investors - highlighting the real-life impact of Assisi^® and Calmer Canine^® technologies on animal health and wellness.

See the Movie and Learn More

Zomedica is excited to see Merv available now on Prime Video.
Gather the family-and the pets- to watch the movie now at https://www.primevideo.com/detail/Merv/0Q49X1W9LOQKCWLSOIJJ0RI2BG

Learn more about the Assisi product line at https://assisi.zomedica.com/merv.

About the Assisi and Calmer Canine Product Lines

Assisi products are a trusted line of non-invasive devices that use targeted pulsed electromagnetic field (tPEMF™) technology to reduce inflammation, relieve pain, and accelerate healing in animals. The Assisi Loop and Assisi Loop Lounge^® products offer safe, drug-free solutions used by veterinarians, rehab specialists, and pet parents worldwide.

The Calmer Canine system, also powered by tPEMF™ technology, is a revolutionary, non-pharmaceutical solution for dogs suffering from anxiety and separation stress. Used by veterinarians and pet parents alike, the Calmer Canine system helps restore balance to anxious pets-naturally and effectively.

About Zomedica

Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi^® line of therapeutic devices, the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, the VetGuardian^® Zero Touch™ monitoring system, and VETIGEL^® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, all designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as it works to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter) :https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

Th.Gonzalez--AT